Logo image of WST

WEST PHARMACEUTICAL SERVICES (WST) Stock Price, Forecast & Analysis

USA - New York Stock Exchange - NYSE:WST - US9553061055 - Common Stock

236.66 USD
-11.12 (-4.49%)
Last: 1/23/2026, 8:04:00 PM
240 USD
+3.34 (+1.41%)
After Hours: 1/23/2026, 8:04:00 PM

WST Key Statistics, Chart & Performance

Key Statistics
Market Cap17.03B
Revenue(TTM)3.02B
Net Income(TTM)491.70M
Shares71.94M
Float71.52M
52 Week High348.9
52 Week Low187.43
Yearly Dividend0.81
Dividend Yield0.32%
EPS(TTM)7.07
PE33.47
Fwd PE30.15
Earnings (Next)02-12
IPO1923-07-27
Sector
GICS SectorHealth Care
GICS IndustryLife Sciences Tools & Services
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
WST short term performance overview.The bars show the price performance of WST in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10 -15 -20

WST long term performance overview.The bars show the price performance of WST in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30

The current stock price of WST is 236.66 USD. In the past month the price decreased by -14.71%. In the past year, price decreased by -31.4%.

WEST PHARMACEUTICAL SERVICES / WST Daily stock chart

WST Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

WST Fundamental Analysis

ChartMill assigns a fundamental rating of 7 / 10 to WST. WST has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

WST Financial Highlights

Over the last trailing twelve months WST reported a non-GAAP Earnings per Share(EPS) of 7.07. The EPS increased by 4.59% compared to the year before.


Industry RankSector Rank
PM (TTM) 16.29%
ROA 11.98%
ROE 16.11%
Debt/Equity 0.07
Chartmill High Growth Momentum
EPS Q2Q%5.95%
Sales Q2Q%7.73%
EPS 1Y (TTM)4.59%
Revenue 1Y (TTM)4.92%

WST Forecast & Estimates

22 analysts have analysed WST and the average price target is 354.05 USD. This implies a price increase of 49.6% is expected in the next year compared to the current price of 236.66.

For the next year, analysts expect an EPS growth of 6.29% and a revenue growth 6.25% for WST


Analysts
Analysts80.91
Price Target354.05 (49.6%)
EPS Next Y6.29%
Revenue Next Year6.25%

WST Ownership

Ownership
Inst Owners97.92%
Ins Owners0.33%
Short Float %2.48%
Short Ratio2.55

About WST

Company Profile

WST logo image West Pharmaceutical Services, Inc. engages in the manufacture and marketing of pharmaceuticals, biologics, vaccines, and consumer healthcare products. The company is headquartered in Exton, Pennsylvania and currently employs 10,600 full-time employees. The firm operates in two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers elastomers & primary containment, drug delivery devices, integrated solutions, and analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers. The Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.

Company Info

WEST PHARMACEUTICAL SERVICES

530 Herman O. West Drive

Exton PENNSYLVANIA 19341 US

CEO: Eric M. Green

Employees: 10600

WST Company Website

WST Investor Relations

Phone: 16105942900

WEST PHARMACEUTICAL SERVICES / WST FAQ

What does WST do?

West Pharmaceutical Services, Inc. engages in the manufacture and marketing of pharmaceuticals, biologics, vaccines, and consumer healthcare products. The company is headquartered in Exton, Pennsylvania and currently employs 10,600 full-time employees. The firm operates in two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers elastomers & primary containment, drug delivery devices, integrated solutions, and analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers. The Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.


What is the current price of WST stock?

The current stock price of WST is 236.66 USD. The price decreased by -4.49% in the last trading session.


What is the dividend status of WEST PHARMACEUTICAL SERVICES?

WEST PHARMACEUTICAL SERVICES (WST) has a dividend yield of 0.32%. The yearly dividend amount is currently 0.81.


How is the ChartMill rating for WEST PHARMACEUTICAL SERVICES?

WST has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 7 out of 10.


What is the ex-dividend date for WST stock?

The next ex-dividend date for WEST PHARMACEUTICAL SERVICES (WST) is January 28, 2026.


What is the employee count for WST stock?

WEST PHARMACEUTICAL SERVICES (WST) currently has 10600 employees.


What is the ownership structure of WEST PHARMACEUTICAL SERVICES (WST)?

You can find the ownership structure of WEST PHARMACEUTICAL SERVICES (WST) on the Ownership tab.